Alvotech
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALVO research report →
Range $5 – $10
Price Chart
About the company
Alvotech, along with its various subsidiaries, is dedicated to the global development and manufacturing of biosimilar pharmaceuticals. Its product offerings span key therapeutic categories, encompassing autoimmune conditions, eye disorders, bone diseases, and cancer. A flagship program for the company is AVT02, a high-concentration biosimilar equivalent to Humira.
- CEO
- Lisa Graver
- IPO
- 2022
- Employees
- 1,279
- HQ
- Luxembourg, LU, LU
Get TickerSpark's AI analysis on ALVO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.44B
- P/E
- -15.02
- Fwd P/E
- 18.12
- PEG
- 0.09
- P/S
- 2.58
- P/B
- -5.00
- EV/EBITDA
- 54.75
- Div Yield
- 0.00%
- Gross Margin
- 61.35%
- Op Margin
- 13.80%
- Net Margin
- -14.43%
- ROE
- 35.22%
- ROIC
- -11.66%
Latest fiscal year · YoY change
- Revenue
- $586.32M+19.7%
- Gross Profit
- $350.76M+15.2%
- Op Income
- $78.21M
- Net Income
- $27.92M+112.0%
- EPS
- $0.10+111.5%
- OCF Growth
- +78.8%
- FCF Growth
- +61.0%
- 52W High
- $9.25
- 52W Low
- $2.94
- 50D MA
- $3.67
- 200D MA
- $4.18
- Beta
- 0.18
- RSI (14)
- 66
- Avg Volume
- 865.30K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Get the ALVO Q2 '26 earnings-call summary
Create a free account to generate an AI summary of this call — key takeaways, results & guidance, CEO/CFO commentary, Q&A, and a bull vs bear read. Ready in about a minute, and it'll be live for everyone.
Create free account →Already have an account? Log in
- Free Float
- 30.5%
- Shares Outstanding
- 338.22M
- Float Shares
- 103.22M
of shares held by institutions
50 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 4.49M | ▲ 141.95K |
| Lodbrok Capital Llp | 181.59K | 0 |
Held by 136 ETFs
Biggest fund positions in ALVO by dollar value.
Our ALVO coverage
Recent articles, reports, and earnings notes.
No research on ALVO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ALVO report →Alvotech: Reiterate Hold On AVT05/AVT06 BLA Resubmissions And Upcoming Catalysts
seekingalpha.com · Aug 20
Alvotech (ALVO) Q2 2026 Earnings Call Transcript
seekingalpha.com · Aug 20
Alvotech Q2 Earnings Call Highlights
marketbeat.com · Aug 20
Alvotech (ALVO) Reports Q2 Loss, Beats Revenue Estimates
zacks.com · Aug 19
Alvotech Announces Financial Results for the First Half of 2026 and Provides a Business Update
globenewswire.com · Aug 19
Alvotech Announces Financial Results for the First Half of 2026 and Provides a Business Update
globenewswire.com · Aug 19
Alvotech to Report Financial Results for H1 2026
globenewswire.com · Aug 10
Alvotech announces successful closure of FDA inspection of manufacturing facility
globenewswire.com · Jul 29
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.